8086 Stock Overview
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Nipro Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,234.50 |
| 52 Week High | JP¥1,302.50 |
| 52 Week Low | JP¥987.00 |
| Beta | 0.11 |
| 1 Month Change | 2.15% |
| 3 Month Change | 3.65% |
| 1 Year Change | 20.91% |
| 3 Year Change | -6.90% |
| 5 Year Change | -10.35% |
| Change since IPO | 106.03% |
Recent News & Updates
Earnings Tell The Story For Nipro Corporation (TSE:8086)
Apr 02
Nipro (TSE:8086) Will Pay A Larger Dividend Than Last Year At ¥15.00
Feb 27Shareholder Returns
| 8086 | JP Medical Equipment | JP Market | |
|---|---|---|---|
| 7D | -3.3% | 1.4% | -2.6% |
| 1Y | 20.9% | 10.7% | 28.4% |
Return vs Industry: 8086 exceeded the JP Medical Equipment industry which returned 10.7% over the past year.
Return vs Market: 8086 underperformed the JP Market which returned 28.4% over the past year.
Price Volatility
| 8086 volatility | |
|---|---|
| 8086 Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 8086 has not had significant price volatility in the past 3 months.
Volatility Over Time: 8086's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 38,770 | Yoshihiko Sano | www.nipro.co.jp |
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical Device business develops, manufactures, and sells medical equipment for injection-infusion and dialysis treatment, and products related to diabetes and cell cultures, as well as the sale of artificial organ-related products. The company’s Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations, as well as logistic and distribution services.
Nipro Corporation Fundamentals Summary
| 8086 fundamental statistics | |
|---|---|
| Market cap | JP¥202.97b |
| Earnings (TTM) | JP¥10.24b |
| Revenue (TTM) | JP¥578.03b |
19.7x
P/E Ratio0.3x
P/S RatioIs 8086 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8086 income statement (TTM) | |
|---|---|
| Revenue | JP¥578.03b |
| Cost of Revenue | JP¥404.46b |
| Gross Profit | JP¥173.58b |
| Other Expenses | JP¥163.34b |
| Earnings | JP¥10.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 10, 2024
| Earnings per share (EPS) | 62.79 |
| Gross Margin | 30.03% |
| Net Profit Margin | 1.77% |
| Debt/Equity Ratio | 218.8% |
How did 8086 perform over the long term?
See historical performance and comparison